Expansion of the Priority Review Voucher Program Under the 21 st Century Cures Act: Implications for Innovation and Public Health

Am J Law Med. 2018 May;44(2-3):329-341. doi: 10.1177/0098858818789430.
No abstract available

MeSH terms

  • Drug Approval / legislation & jurisprudence*
  • Drug Industry
  • Health Policy / legislation & jurisprudence*
  • Humans
  • Neglected Diseases / drug therapy
  • Orphan Drug Production / legislation & jurisprudence*
  • United States
  • United States Food and Drug Administration